A Crucial Summer Awaits for Bayer’s Legal and Financial Future

The German pharmaceutical and agricultural giant Bayer finds itself at a critical juncture. Its immediate prospects hinge on two pivotal legal developments this summer, even as the company navigates a complex financial landscape marked by litigation costs and cash flow pressures.

Legal Crossroads: Settlement and Supreme Court

Two major legal events are set to define Bayer’s trajectory. On March 4, a judge in St. Louis granted preliminary approval for a class settlement addressing current and future lawsuits linking its Roundup weedkiller to Non-Hodgkin Lymphoma. The framework allocates up to $7.25 billion for approximately 65,000 outstanding claims. However, CEO Bill Anderson has emphasized the settlement’s success depends on claimant participation rates coming “very close” to 100%; Bayer retains the right to withdraw the agreement if this high threshold is not met.

Concurrently, the company is pursuing a separate legal strategy. The U.S. Supreme Court is scheduled to hear arguments on April 27 regarding whether federal law preempts state-level failure-to-warn claims concerning Roundup. A ruling, expected in the latter half of June, in Bayer’s favor could invalidate a substantial portion of remaining litigation. An unfavorable decision, however, would signal that the class settlement alone is insufficient to resolve its legal overhang. Provisions for ongoing litigation are anticipated to rise to around €11.8 billion as a result of the settlement, with €9.6 billion earmarked for glyphosate-related matters.

2025 Performance: Mixed Results Amid Goal Achievement

Bayer met its key targets for the 2025 fiscal year. Group sales reached €45.6 billion, representing a currency-adjusted increase of 1.1%. Earnings before interest, taxes, depreciation, and amortization (EBITDA) before special items came in at €9.7 billion. Despite this operational achievement, the bottom line showed a net loss of €3.6 billion, driven by significant special expenses related to ongoing legal proceedings.

A positive note was an 8.5% reduction in net financial debt to approximately €29.8 billion. Conversely, free cash flow contracted sharply by nearly one-third to €2.1 billion.

Should investors sell immediately? Or is it worth buying Bayer?

Performance within the agricultural division (Crop Science) was uneven. The corn seed segment delivered strong growth of 13.2%, fueled by expanded cultivation areas and a resolved licensing agreement. This was offset by challenges in soybean and cotton seed, adversely affected by the loss of Dicamba product registration in the United States.

2026 Guidance: Operational Stability Versus Cash Drain

Looking ahead, management forecasts 2026 sales between €44 billion and €46 billion. It expects EBITDA before special items to land in a range of €9.1 billion to €9.6 billion. The upper end of this guidance slightly misses the average analyst estimate of €9.67 billion.

More concerning is the outlook for free cash flow, which Bayer anticipates will be deeply negative, between -€1.5 billion and -€2.5 billion. This projection incorporates roughly €5 billion in anticipated litigation payouts. Consequently, net financial debt is expected to climb back to between €32 billion and €33 billion by year-end. The company has ruled out a capital increase to address this.

Market Sentiment and the Path Forward

Bayer’s shares currently trade at €39.77, approximately 19% below their 52-week high of €49.17. A Relative Strength Index (RSI) reading of 19.6 indicates the stock is in deeply oversold territory. Whether this leads to a sustainable recovery will largely depend on the summer’s legal outcomes. The combination of the class settlement’s fate and the Supreme Court’s ruling has the potential to fundamentally reshape Bayer’s litigation framework—for better or worse—and finally determine if the company can shed the burden that has weighed on it for years.